Last reviewed · How we verify

ER OROS paliperidone and Olanzapine — Competitive Intelligence Brief

ER OROS paliperidone and Olanzapine (ER OROS paliperidone and Olanzapine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic combination. Area: Psychiatry / Neurology.

phase 3 Atypical antipsychotic combination Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ER OROS paliperidone and Olanzapine (ER OROS paliperidone and Olanzapine) — Xian-Janssen Pharmaceutical Ltd.. This combination of an extended-release atypical antipsychotic (paliperidone) and another atypical antipsychotic (olanzapine) works by blocking dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ER OROS paliperidone and Olanzapine TARGET ER OROS paliperidone and Olanzapine Xian-Janssen Pharmaceutical Ltd. phase 3 Atypical antipsychotic combination Dopamine D2 receptor, Serotonin 5-HT2A receptor
quetiapine fumarate vs risperidone quetiapine fumarate vs risperidone AstraZeneca marketed Atypical antipsychotic Dopamine D2 receptor, serotonin 5-HT2A receptor
Quetiapine Immediate Release Quetiapine Immediate Release AstraZeneca marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
risperidone (Risperdal) risperidone (Risperdal) University of South Florida marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
Oral Olanzapine Oral Olanzapine Eli Lilly and Company marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
Lithium carbonate + perospirone hydrochloride Lithium carbonate + perospirone hydrochloride Shanghai Mental Health Center marketed Mood stabilizer + atypical antipsychotic combination Inositol monophosphatase, GSK-3 (lithium); dopamine D2 receptor, serotonin 5-HT2A receptor (perospirone)
quetiapine (Seroquel) XR quetiapine (Seroquel) XR Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc. marketed Atypical antipsychotic Dopamine D2 receptor, serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic combination class)

  1. Changhua Christian Hospital · 1 drug in this class
  2. Heinrich-Heine University, Duesseldorf · 1 drug in this class
  3. Taichung Veterans General Hospital · 1 drug in this class
  4. Xian-Janssen Pharmaceutical Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ER OROS paliperidone and Olanzapine — Competitive Intelligence Brief. https://druglandscape.com/ci/er-oros-paliperidone-and-olanzapine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: